Bracco has invested in Chinese facilities to produce and ship contrast media. The investments are being made through a joint venture with Shanghai-based Sine Pharmaceutical. The Bracco-Sine production plant opened in June in Shanghai's high-tech district. It will focus on the final cycle in contrast media production. Chinese workers will formulate drug solutions from basic ingredients sent from Italy, then prepare, seal, and sterilize individual doses.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.